Business
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Soci
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data","length":168,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia.","length":479,"tagName":"p"},{"type":"text","content":"Researchers including Christopher Laing, MD of Sutter Health in California, will present the clinical data abstract, “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors.” The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP (Trans-Arterial Micro-Perfusion) therapy platform enabled by RenovoCath catheter, a double-balloon drug-delivery device, and how these measurements along with other variables can play a role in optimizing targeted delivery of chemotherapy in difficult-to-treat tumors.","length":660,"tagName":"p"},{"type":"image","alt":"Illustration of RenovoCath delivering chemotherapy to tumor site via peripheral vascular system","displaySize":"","headline":null,"caption":"Illustration of RenovoCath delivering chemotherapy to tumor site via peripheral vascular system","className":"","disableSlideshowImg":false,"size":{"original":{"width":346,"height":305,"url":"https://media.zenfs.com/en/globenewswire.com/e5...